Back

Select your region

Schedule a cord blood consultation

Make an appointment

Stem Cells
Therapies

Stem Cells Therapies

The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).

FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.

Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.

Check the full list of patients who received stem cell therapy derived from FamiCord labs.

List last update: 06.2026

List of patients who received stem cells from FamiCord Group laboratories

List of patients who received stem cells from FamiCord Group laboratories
Lp. Source Source type Diagnosis Medical field Year of application Therapy Country Age of recipient
1201 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Australia 71
1202 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 76
1203 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Canada 66
1204 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 74
1205 Apheresis Allogeneic Morbus Hodgkin Hematology 2025 Standard Therapy Germany 21
1206 Apheresis Allogeneic Myelodysplastic Disorders Hematology 2025 Standard Therapy France 66
1207 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy USA 65
1208 Apheresis Allogeneic T Lymphoblastic Lymphoma Hematology 2025 Standard Therapy Portugal 25
1209 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Romania 29
1210 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 37
1211 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 49
1212 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 32
1213 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 72
1214 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 43
1215 Apheresis Allogeneic Hodking lymphoma Hematology 2025 Standard Therapy Serbia 32
1216 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Canada 66
1217 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 71
1218 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 66
1219 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 68
1220 Apheresis Allogeneic OMDS/ Myeloproliferative Neoplasie Hematology 2025 Standard Therapy Switzerland 46
1221 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 3
1222 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 75
1223 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 58
1224 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Greece 63
1225 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 64
1226 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 65
1227 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Spain 49
1228 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 30
1229 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 66
1230 Apheresis Allogeneic Chronic Lymphocyte Leukemia Hematology 2025 Standard Therapy Canada 55
1231 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2025 Standard Therapy USA 64
1232 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 16
1233 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy USA 73
1234 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Ukraine 47
1235 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 64
1236 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 67
1237 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2025 Standard Therapy USA 65
1238 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 58
1239 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy Germany 57
1240 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy RUSSIAN FEDERATION 22
1241 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Ukraine 33
1242 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Slovakia 41
1243 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Greece 54
1244 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Ukraine 46
1245 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Argentina 26
1246 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 70
1247 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 59
1248 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 34
1249 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Norway 53
1250 Apheresis Allogeneic Other Immune System Hematology 2025 Standard Therapy USA 19
1251 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 6
1252 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 68
1253 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 72
1254 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Germany 64
1255 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy United Kingdom 33
1256 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Italy 63
1257 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Lithuania 33
1258 Apheresis Autologous Central Nervous System Lymphoma Hematology 2025 Standard Therapy Germany 61
1259 Apheresis Allogeneic Acute lymphocytic leukemia Hematology 2025 Standard Therapy Germany 51
1260 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 64
1261 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 54
1262 Apheresis Autologous Testicular tumor Hematology 2025 Standard Therapy Germany 42
1263 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 52
1264 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 49
1265 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 73
1266 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 62
1267 Apheresis Autologous Lymphoma Hodgkin Hematology 2025 Standard Therapy Portugal 39
1268 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 60
1269 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 70
1270 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 64
1271 Apheresis Autologous T-Cell Lymphoma Hematology 2025 Standard Therapy Germany 60
1272 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 62
1273 Apheresis Autologous Mantle Cell Lymphoma Hematology 2025 Standard Therapy Germany 60
1274 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 43
1275 Apheresis Allogeneic Myeofibrosis Hematology 2025 Standard Therapy Poland 37
1276 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Russia 22
1277 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy NETHERLANDS 66
1278 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 57
1279 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 56
1280 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 78
1281 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 65
1282 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 53
1283 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Portugal 41
1284 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 56
1285 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 22
1286 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 36
1287 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Canada 65
1288 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 71
1289 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Sweden 73
1290 Apheresis Allogeneic NK LGL Leukemia Hematology 2025 Standard Therapy USA 42
1291 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Italy 29
1292 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 71
1293 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 68
1294 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Czechia 64
1295 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 10
1296 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Brazil 57
1297 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Lithuania 21
1298 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Lithuania 54
1299 Apheresis Allogeneic Richter Transformation From CLL Hematology 2025 Standard Therapy Poland 55
1300 Apheresis Allogeneic Richter Transformation From CLL Hematology 2025 Standard Therapy Poland 63